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Background: Tagraxofusp is a novel targeted therapy directed to the
interleukin-3 receptor (CD123). Tagraxofusp is comprised of human IL-3
recombinantly fused to a truncated diphtheria toxin (DT) payload engi-
neered such that IL-3 replaces the native DT receptor-binding domain. In
this way, the IL-3 domain of tagraxofusp directs the cytotoxic DT payload
to cells expressing CD123. Upon internalization, tagraxofusp irreversibly
inhibits protein synthesis and induces apoptosis of the target cell.
Tagraxofusp was recently approved by the FDA for the treatment of
patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a
malignancy derived from the plasmacytoid dendritic cell (pDC) precursor.
pDCs are immune cells that express CD123, secrete IFN-a, and play a
role in inflammation and disease pathogenesis observed in systemic scle-
rosis (SSc) patients1,2. Therapeutic depletion of pDCs or attenuation of
pDC function may represent a novel approach to treating SSc patients.
Objectives: To assess the ability of tagraxofusp to selectively deplete
pDCs from SSc patients ex vivo.
Methods: Patients fulfilled the 2013 ACR/EULAR classification criteria for
SSc3. PBMCs from either SSc patients or healthy volunteers (HV) were
prepared using Ficoll-Paque density gradient from fresh blood. pDCs were
isolated from PBMCs as previously described and used to enrich the fre-
quency of pDCs in an additional draw of PBMCs4. pDC-enriched PBMCs
(3-6% pDCs) were cultured at 2x105 cells per well in the presence or
absence of CpG-274 (0.5 mM) to activate pDCs and then incubated with
tagraxofusp (0.01-100 ng/ml, 0.17 pM-1.7 nM) at 37°C, 5% CO2, and
95% humidity. After 24 h of culture, pDC survival was assessed by flow
cytometry (CD14-, CD3- BDCA4+ CD123+), and supernatants were col-
lected for cytokine quantification by a multiplexed Luminex assay.
Changes in gene expression were measured by PCR on 10 mg cDNA,
and calculated based on relative threshold cycle and expression of a
ubiquitin housekeeping gene.
Results: Tagraxofusp was cytotoxic towards pDCs from both HV (n=5)
and SSc donors (n=5) to a similar extent. The ED50 of tagraxofusp in
pDCs from HV and SSc was 4.3 and 3.2 ng/ml (74.4 and 55.4 pM),
respectively; no effect was observed on B or T cells across the tagraxo-
fusp dose range tested (Fig.1A). Tagraxofusp-mediated pDC depletion
was further accompanied by a 68-fold reduction in secreted IFN-a and a
3-fold downregulation of GBP, a type 1 IFN-induced gene (Fig. 1B).
Conclusion: Tagraxofusp is a novel CD123-targeted therapy that is cyto-
toxic towards pDCs from SSc patients. These data present a novel
approach of targeting pDCs in the treatment of SSc, and a clinical trial
is under design.
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Background: Systemic Sclerosis (SSc) is a chronic systemic disease fre-
quently leading to disability and low quality of life. Chronic pain (CP),
due to severe disease complications and internal organs involvement, is
often underestimated. Based on available data around a 60-70% of
patient with SSc suffer of chronic pain but we still lacking of fine tools
to better evaluate it and follow up patients
Objectives: Evaluate pain in SSc patients, in terms of its intensity, sen-
sory and affective components, the interference with physical and social
activities, impact on quality of life and correlation with main SSc clinical
manifestations.
Methods: From January 2013 to January 2018 we retrospectively eval-
uated 98 patients with a diagnosis of SSc [F/M=87/11; Limited/Diffuse
SSc 63/35 anti-Scl70/ACA/ANA nucleolar positivity 45/39/14; mean age
55,6 ± 12,6 DS; mean disease duration 9,9 ± 7,6 DS] according to
2013 ACR/EULAR criteria; 47 patients with a diagnosis of chronic head-
ache (CH) as defined by the International Classification for Headache
Disorders, Third Edition beta version (ICHD-3 beta) criteria [F/M 37/10;
mean age 52,6 ± 14,2 DS; mean disease duration: 7 ±2 yrs DS] and
46 patients with Rheumatoid Arthritis [F/M 36/10, mean age 61±13, mean
disease duration 10±2 yrs, DS]. All patients fulfilled self-complying ques-
tionnaires for the evaluation of pain and quality of life: Visual Analogic
Scale (VAS), Numeric Rating Scale (NRS), Short Form-McGill Pain Ques-
tionnaire (SF-MPQ), Brief Pain Inventory Score (BPI) e Health Assess-
ment Questionnaire (HAQ).
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Results: SSc patients started to suffer of CP in younger ages compared
to AR/CH cohort but patients suffering of CH have higher mean scores
in all questionnaires compared to AR/SSc. CH patients, have higher
mean score in SFMPQ-sensory and affectory. Hundred percent (100%) of
AR patients suffered of chronic pain. They, generally, had higher scores
than SSc patients with a prevalence of the affectory component. The
83.9% (67/75 pts) of SSc patients experienced chronic pain [SF-MPQ
PRI: 6.25±8.34DS; SF-MPQ PPI: 1.69±1.34DS; BPI-fattore1: 13.37
±11.26DS; VAS: 40.7±29.6DS; NRS: 4.08±2.98DS] and in a great major-
ity (84%) that pain interfered with their working activities and social lifes.
Fortyeight percent of SSc patients had digital ulcers and 41.3% had mus-
culoskeletal involvement. Pain used to correlate with both of them
[p=0.004; p=0.041]. In patients with DUs, affectory component of pain
overuled on the sensory one
Conclusion: SSc patients frequently experience chronic pain and particu-
larly those who have a history of active DUs and musculoskeletal
involvement. By the way, it seems that the BPI questionnaire could be
more suitable than VAS or NRS in assessing DUs’ pain. Furthermore it
provides useful information on the impact of CP on social life and work
impairment. Otherwise, SF_MPQ allows clinicians to better discriminate
affective or sensory components of pain.
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Background: Dysphagia represents a frequent and disabling symptom in
patients with Idiopathic Inflammatory Myopathies (IIMs) and it has been
recently included in the new ACR/EULAR classification criteria for IIMs.
Despite the clinical relevance, dysphagia assessment in IIMs is not cur-
rently standardized and evaluation tools are highly variable between differ-
ent centers. Functional Endoscopic Evaluation of Swallowing (FESS) is
an exam that allows, by using nasal endoscopy, the direct evaluation of
anatomic structures and swallowing abilities in different swallowing phase.
In fact, FESS could help the identification of different problems leading to
dysphagia occurrence and to related dysphagia problems. Thanks to
these characteristics, FESS for ENT specialists is the gold standard tech-
nique for evaluating swallowing functions. However, no studies so far
have investigated the role of FESS in the assessment of IIMs and we
are completely lacking a semeiotic description of FESS findings in these
patients.
Objectives: To provide the first semeiotic description of swallowing altera-
tions evidenced by FEES in a cohort of IIMs patients.
Methods: We retrospectively reviewed the FEES findings of IIMs patients
performed at our hospital.
Results: We enrolled 19 patients with a diagnosis of IIMs (10 patients
were positive for a myositis specific antibody), of these 16 (84%)
reported symptomatic dysphagia. We divided patients into 3 groups based
on levels of peripheral muscle strength. Six patients (32%) had no clini-
cal sign of active muscle disease (MRC scale 5, median CK 51 mU/ml,
IQR 35-235), 5 patients (26%) had a mild reduction in muscle strength
(MRC scale 4, median CK 76, IQR 54-220) and 8 patients (42%)
showed a moderate-severe reduction in muscle strength (MRC scale £3,
media CK 1440, IQR 628-6180). The 67% of patients without muscle dis-
ease activity showed an impairment in the oral phase of swallowing for
solids and the 33% for fluids; 33% had a reduction in the activation of
the pharyngeal phase of swallowing for both fluids and solids; only 17%
of patients showed any sign of penetration, aspiration or pharyngeal resi-
due for both solids and fluids. In the group of patients with moderate
muscle activity, 80% of patients showed impairment in the oral phase of
swallowing for solids and 40% for fluids; 60% had a reduction in the
activation of the pharyngeal phase of swallowing for solids while 40% for
fluids; 40% of patients showed signs of penetration, aspiration or phar-
yngeal residue for both solids and fluids. Finally, in the group of patients
with severe muscle disease activity, 88% of patients showed an impair-
ment in the oral phase of swallowing for solids and 50% for fluids; 63%
had a reduction in the activation of the pharyngeal phase of swallowing
for solids while 50% for fluids; 75% of patients showed signs of penetra-
tion, aspiration or pharyngeal residue for both solids and fluids. The 15%
of all patients (3 cases, 1 from each group of muscle activity) showed a
dysfunction in the upper esophageal sphincter. Of note, 3 patients (15%;
1 with moderate and 2 with severe muscle disease activity) required
nutrition through nasogastric tube.
Conclusion: We showed that FESS study identified swallowing dysfunc-
tions in both the oral and pharyngeal phases of swallowing. Swallowing
dysfunctions were more prevalent in patients with greater muscle involve-
ment; however, alterations were not rare also in patients with no clinical
signs of muscle activity and, in particular, in the few patients without
reported symptoms of dysphagia. FEES appears as a useful tool for the
evaluation of dysphagia in IIMs.
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Background: Polymyositis (PM) and dermatomyositis (DM) are idiopathic
inflammatory myopathies that mainly involve the muscles, skin, lungs, and
heart. PM/DM are frequently complicated by interstitial lung disease (ILD)
that causes increased mortality. Anti-aminoacyl tRNA synthetase (ARS)
antibody and anti-melanoma differentiation-associated gene 5 (MDA5) anti-
body are associated with complications of ILD. Anti-ARS antibody-positive
PM/DM-ILD responds well to immunosuppressive therapy and has a good
short-term prognosis but a high rate of relapse over the long term. In
contrast, anti-MDA5 antibody-positive PM/DM-ILD responds poorly to
immunosuppressive therapy, and its prognosis is poor. Recently, a num-
ber of cytokines have been implicated in the pathomechanism and
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